131 related articles for article (PubMed ID: 38853183)
1. Farnesyltransferase inhibitor lonafarnib suppresses respiratory syncytial virus infection by blocking conformational change of fusion glycoprotein.
Yang Q; Xue B; Liu F; Lu Y; Tang J; Yan M; Wu Q; Chen R; Zhou A; Liu L; Liu J; Qu C; Wu Q; Fu M; Zhong J; Dong J; Chen S; Wang F; Zhou Y; Zheng J; Peng W; Shang J; Chen X
Signal Transduct Target Ther; 2024 Jun; 9(1):144. PubMed ID: 38853183
[TBL] [Abstract][Full Text] [Related]
2. Drug repurposing screen identifies lonafarnib as respiratory syncytial virus fusion protein inhibitor.
Sake SM; Zhang X; Rajak MK; Urbanek-Quaing M; Carpentier A; Gunesch AP; Grethe C; Matthaei A; Rückert J; Galloux M; Larcher T; Le Goffic R; Hontonnou F; Chatterjee AK; Johnson K; Morwood K; Rox K; Elgaher WAM; Huang J; Wetzke M; Hansen G; Fischer N; Eléouët JF; Rameix-Welti MA; Hirsch AKH; Herold E; Empting M; Lauber C; Schulz TF; Krey T; Haid S; Pietschmann T
Nat Commun; 2024 Feb; 15(1):1173. PubMed ID: 38332002
[TBL] [Abstract][Full Text] [Related]
3. GS-5806 Inhibits a Broad Range of Respiratory Syncytial Virus Clinical Isolates by Blocking the Virus-Cell Fusion Process.
Perron M; Stray K; Kinkade A; Theodore D; Lee G; Eisenberg E; Sangi M; Gilbert BE; Jordan R; Piedra PA; Toms GL; Mackman R; Cihlar T
Antimicrob Agents Chemother; 2015 Dec; 60(3):1264-73. PubMed ID: 26666922
[TBL] [Abstract][Full Text] [Related]
4. Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge.
Gilbert BE; Patel N; Lu H; Liu Y; Guebre-Xabier M; Piedra PA; Glenn G; Ellingsworth L; Smith G
Vaccine; 2018 Dec; 36(52):8069-8078. PubMed ID: 30389195
[TBL] [Abstract][Full Text] [Related]
5. Two novel fusion inhibitors of human respiratory syncytial virus.
Lundin A; Bergström T; Bendrioua L; Kann N; Adamiak B; Trybala E
Antiviral Res; 2010 Dec; 88(3):317-24. PubMed ID: 20965215
[TBL] [Abstract][Full Text] [Related]
6. Respiratory syncytial virus entry inhibitors targeting the F protein.
Sun Z; Pan Y; Jiang S; Lu L
Viruses; 2013 Jan; 5(1):211-25. PubMed ID: 23325327
[TBL] [Abstract][Full Text] [Related]
7. Comparative Therapeutic Potential of ALX-0171 and Palivizumab against Respiratory Syncytial Virus Clinical Isolate Infection of Well-Differentiated Primary Pediatric Bronchial Epithelial Cell Cultures.
Broadbent L; Parke HG; Ferguson LJ; Millar A; Shields MD; Detalle L; Power UF
Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31767728
[TBL] [Abstract][Full Text] [Related]
8. Discovery of a Prefusion Respiratory Syncytial Virus F-Specific Monoclonal Antibody That Provides Greater
Zhao M; Zheng ZZ; Chen M; Modjarrad K; Zhang W; Zhan LT; Cao JL; Sun YP; McLellan JS; Graham BS; Xia NS
J Virol; 2017 Aug; 91(15):. PubMed ID: 28539438
[TBL] [Abstract][Full Text] [Related]
9. Small molecule inhibits respiratory syncytial virus entry and infection by blocking the interaction of the viral fusion protein with the cell membrane.
Tang W; Li M; Liu Y; Liang N; Yang Z; Zhao Y; Wu S; Lu S; Li Y; Liu F
FASEB J; 2019 Mar; 33(3):4287-4299. PubMed ID: 30571312
[TBL] [Abstract][Full Text] [Related]
10. Analysis of respiratory syncytial virus fusion protein from clinical isolates of Korean children in palivizumab era, 2009-2015.
Choi SH; Park KS; Kim YJ
J Infect Chemother; 2019 Jul; 25(7):514-519. PubMed ID: 30885457
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of Cross-Resistance to Fusion Inhibitors Conferred by the K394R Mutation in Respiratory Syncytial Virus Fusion Protein.
Tang W; Li Y; Song Q; Wang Z; Li M; Zhang Q; Wang Y; Ye W; Li Y
J Virol; 2021 Sep; 95(20):e0120521. PubMed ID: 34379500
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological Characterization of TP0591816, a Novel Macrocyclic Respiratory Syncytial Virus Fusion Inhibitor with Antiviral Activity against F Protein Mutants.
Yoshida I; Arikawa K; Honma Y; Inatani S; Yoshinaga M; Sugiyama H
Antimicrob Agents Chemother; 2020 Dec; 65(1):. PubMed ID: 33046486
[TBL] [Abstract][Full Text] [Related]
13. Oral efficacy of a respiratory syncytial virus inhibitor in rodent models of infection.
Cianci C; Genovesi EV; Lamb L; Medina I; Yang Z; Zadjura L; Yang H; D'Arienzo C; Sin N; Yu KL; Combrink K; Li Z; Colonno R; Meanwell N; Clark J; Krystal M
Antimicrob Agents Chemother; 2004 Jul; 48(7):2448-54. PubMed ID: 15215093
[TBL] [Abstract][Full Text] [Related]
14. A Pseudovirus-Based Entry Assay to Evaluate Neutralizing Activity against Respiratory Syncytial Virus.
Hu L; Jiang J; Tang Y; Mei L; Wu L; Li L; Chen H; Long F; Xiao J; Peng T
Viruses; 2023 Jul; 15(7):. PubMed ID: 37515234
[TBL] [Abstract][Full Text] [Related]
15. Development of bioluminescence imaging of respiratory syncytial virus (RSV) in virus-infected live mice and its use for evaluation of therapeutics and vaccines.
Fuentes S; Arenas D; Moore MM; Golding H; Khurana S
Vaccine; 2017 Jan; 35(4):694-702. PubMed ID: 27989627
[TBL] [Abstract][Full Text] [Related]
16. Parainfluenza Virus 5 Expressing Wild-Type or Prefusion Respiratory Syncytial Virus (RSV) Fusion Protein Protects Mice and Cotton Rats from RSV Challenge.
Phan SI; Zengel JR; Wei H; Li Z; Wang D; He B
J Virol; 2017 Oct; 91(19):. PubMed ID: 28747496
[TBL] [Abstract][Full Text] [Related]
17. Discovery of Ziresovir as a Potent, Selective, and Orally Bioavailable Respiratory Syncytial Virus Fusion Protein Inhibitor.
Zheng X; Gao L; Wang L; Liang C; Wang B; Liu Y; Feng S; Zhang B; Zhou M; Yu X; Xiang K; Chen L; Guo T; Shen HC; Zou G; Wu JZ; Yun H
J Med Chem; 2019 Jul; 62(13):6003-6014. PubMed ID: 31194544
[TBL] [Abstract][Full Text] [Related]
18. Molecular mechanism of respiratory syncytial virus fusion inhibitors.
Battles MB; Langedijk JP; Furmanova-Hollenstein P; Chaiwatpongsakorn S; Costello HM; Kwanten L; Vranckx L; Vink P; Jaensch S; Jonckers TH; Koul A; Arnoult E; Peeples ME; Roymans D; McLellan JS
Nat Chem Biol; 2016 Feb; 12(2):87-93. PubMed ID: 26641933
[TBL] [Abstract][Full Text] [Related]
19. Labyrinthopeptins as virolytic inhibitors of respiratory syncytial virus cell entry.
Blockus S; Sake SM; Wetzke M; Grethe C; Graalmann T; Pils M; Le Goffic R; Galloux M; Prochnow H; Rox K; Hüttel S; Rupcic Z; Wiegmann B; Dijkman R; Rameix-Welti MA; Eléouët JF; Duprex WP; Thiel V; Hansen G; Brönstrup M; Haid S; Pietschmann T
Antiviral Res; 2020 May; 177():104774. PubMed ID: 32197980
[TBL] [Abstract][Full Text] [Related]
20. Respiratory syncytial virus-neutralizing monoclonal antibodies motavizumab and palivizumab inhibit fusion.
Huang K; Incognito L; Cheng X; Ulbrandt ND; Wu H
J Virol; 2010 Aug; 84(16):8132-40. PubMed ID: 20519399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
